«

»

Should Medicare pay for Aduhelm?

In June, the FDA approved aducanumab (Aduhelm) to treat patients with Alzheimer’s disease using the agency’s accelerated approval pathway, despite significant concerns about the evidence regarding the drug’s safety and effectiveness. The agency’s approval decision contradicted the recommendations of its own advisory committee, which voted overwhelmingly against the evidence presented in support of the drug. Soon after Read more… Should Medicare pay for Aduhelm? originally appeared in KevinMD.com.

Read the full post at KevinMD.com
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive